Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A 3-day anti-Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection
Autore:
Hsieh, YH; Lin, HJ; Tseng, GY; Perng, CL; Chang, FY; Lee, SD;
Indirizzi:
VGH Taipei, Dept Med, Div Gastroenterol, Taipei 11217, Taiwan VGH Taipei Taipei Taiwan 11217 , Div Gastroenterol, Taipei 11217, Taiwan Natl Yang Ming Univ, Sch Med, Div Gastroenterol, Taipei, Taiwan Natl Yang Ming Univ Taipei Taiwan ed, Div Gastroenterol, Taipei, Taiwan
Titolo Testata:
HEPATO-GASTROENTEROLOGY
fascicolo: 40, volume: 48, anno: 2001,
pagine: 1078 - 1081
SICI:
0172-6390(200107/08)48:40<1078:A3APTI>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
SUCCESSFUL ENDOSCOPIC THERAPY; RANDOMIZED COMPARATIVE TRIAL; DOSE TRIPLE THERAPY; QUADRUPLE THERAPY; FOLLOW-UP; OMEPRAZOLE; LANSOPRAZOLE; BISMUTH; CURE;
Keywords:
Helicobacter pylori; peptic; ulcer bleeding; triple therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Lin, HJ VGH Taipei, Dept Med, Div Gastroenterol, Shih Pai Rd,Sec 2, Taipei11217, Taiwan VGH Taipei Shih Pai Rd,Sec 2 Taipei Taiwan 11217 ei 11217, Taiwan
Citazione:
Y.H. Hsieh et al., "A 3-day anti-Helicobacter pylori therapy is a good alternative for bleeding peptic ulcer patients with Helicobacter pylori infection", HEP-GASTRO, 48(40), 2001, pp. 1078-1081

Abstract

Background/Aims: One-week triple therapy has been recommended as a standard regimen for eradicating Helicobacter pylori infection. The emergence of antibiotic-resistant strains, adverse drug effects, poor compliance and highcost of therapy add problems to the management of these patients. In this study, we assessed whether a 3-day triple therapy could be effective in eradicating Helicobacter pylori infection in bleeding peptic ulcer patients. Methodology: Peptic ulcer patients with Helicobacter pylori infection wereenrolled in this study. Patients enrolled at the outpatient department (group A) received a 7-day oral regimen: bismuth subcitrate colloid 300mg + amoxicillin 500mg + metronidazole 250mg four times per day. Patients who wereadmitted to the wards due to peptic ulcer bleeding (group 13) received a 3-day regimen including omeprazole 40mg intravenously every 6 hours, amoxicillin 500mg + metronidazole 250mg orally four times daily after hemostasis had been achieved. Patients of both groups received omeprazole 20mg once perday or cimetidine 400mg twice daily per os for at least one month after anti-Helicobacter pylori therapy. We followed every patient endoscopically two months after anti-Helicobacter pylori therapy. Results: From June 1997 to April 1999, a total of 57 patients (30 in groupA and 27 in group 13) with gastric or duodenal ulcer and Helicobacter pylori infection completed anti-Helicobacter pylori therapy. Two months after anti-Helicobacter pylori therapy, peptic ulcer was found to be healed with ascar in 26 (86.7%) of group A and 23 (85.2%) of group B (P >0.1). The eradication rates of Helicobacter pylori in the two groups were not significantly different in an intention-to-treat analysis [group A: 78.8% (26/33), 95%Cl: 64.9-92.7%; group 13: 80% (24/30), 95% Cl: 65.7-94.3%, P >0.1] and in a per protocol analysis [group A: 86.7% (26/30),95% Cl: 74.5-98.9%, group 13: 88.9% (24/27), 95% Cl: 77.1-100.7%, P >0.1]. Fewer side effects occurredin group B (3/30) than those in group A (7/33) (P >0.1). Conclusions: In patients with peptic ulcer bleeding a 3-day anti-Helicobacter pylori therapy is a good alternative for eradicating Helicobacter pylori infection.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 10:41:39